RECENT NEWS 17 February 2014
INV-17 Autoimmune Disease Preclinical Findings presented in BioCentury Week in Review
21 January 2014
Innovimmune ROR Gamma Inhibitor Prevents Multiple Sclerosis in Mice

INNOVIMMUNE is a specialty Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule NME immunomodulatory drugs for the treatment of Autoimmune and ImmunoInflammatory Diseases.